Pharmacokinetic-Based Drug–Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review

References

• FerlayJ, Steliarova-FoucherE, Lortet-TieulentJ, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi:10.1016/j.ejca.2012.12.02723485231
   PubMed Web of Science ®Google Scholar
• TabchiS, KourieHR, KlasterskyJ. Concurrent driver mutations/rearrangements in non-small-cell lung cancer. Curr Opin Oncol. 2017;29(2):118–122. doi:10.1097/CCO.000000000000035328027105
   PubMed Web of Science ®Google Scholar
• da Cunha SantosG, ShepherdFA, TsaoMS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6(1):49–69. doi:10.1146/annurev-pathol-011110-13020620887192
   PubMed Web of Science ®Google Scholar
• LeeDH. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures. Pharmacol Ther. 2017;174:1–21. doi:10.1016/j.pharmthera.2017.02.00128167215
   PubMed Web of Science ®Google Scholar
• MoriM, HayashiH, FukudaM, et al. Clinical and computed tomography characteristics of non-small cell lung cancer with ALK gene rearrangement: comparison with EGFR mutation and ALK/EGFR-negative lung cancer. Thorac Cancer. 2019;10(4):872–879. doi:10.1111/1759-7714.1301730811109
   PubMed Web of Science ®Google Scholar
• RoskoskiR Jr. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers. Pharmacol Res. 2017;117:343–356. doi:10.1016/j.phrs.2017.01.00728077299
   PubMed Web of Science ®Google Scholar
• SpagnuoloA1, MaioneP1, GridelliC. Evolution in the treatment landscape of non-small cell lung cancer with ALK gene alterations: from the first- to third-generation of ALK inhibitors. Expert Opin Emerg Drugs. 2018;23(3):231–241. doi:10.1080/14728214.2018.152790230251885
   PubMed Web of Science ®Google Scholar
• TannenbaumC, SheehanNL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533–544. doi:10.1586/17512433.2014.91011124745854
   PubMed Web of Science ®Google Scholar
• KucharczukCR, GanetskyA, VozniakJM. Drug-drug interactions, safety, and pharmacokinetics of EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. J Adv Pract Oncol. 2018;9(2):189–200.30588353
   PubMedGoogle Scholar
• van LeeuwenRW, van GelderT, MathijssenRH, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–e326. doi:10.1016/S1470-2045(13)70579-524988935
   PubMed Web of Science ®Google Scholar
• ScriptureCD, FiggWD. Drug interactions in cancer therapy. Nat Rev Cancer. 2006;6(7):546–558. doi:10.1038/nrc188716794637
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• European Medicines Agency. Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Accessed 12 1, 2019.
   Google Scholar
• HamiltonG1, RathB, BurghuberO. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol. 2015;11(5):835–842. doi:10.1517/17425255.2015.102168525732197
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205755s016lbl.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• European Medicines Agency. Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• MorcosPN, YuL, BogmanK, et al. Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica. 2017;47(3):217–229. doi:10.1080/00498254.2016.117982127180975
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Accessed 12 1, 2019.
   Google Scholar
• European Medicines Agency. Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• US Food and Drug Administration. Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208772s004lbl.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• European Medicines Agency. Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• US Food and Drug Administration. Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf. Accessed 12 1, 2019.
   Google Scholar
• European Medicines Agency. Product information. Available from: https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Accessed 12 1, 2019.
   Google Scholar
• US Food and Drug Administration. Label. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf. Accessed 49, 2020 Accessed 3 6, 2020.
   Google Scholar
• European Medicines Agency. Multi-discipline review. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.pdf. Accessed 12 1, 2019.
   Google Scholar
• RobertsAG, GibbsME. Mechanisms and the clinical relevance of complex drug-drug interactions. Clin Pharmacol. 2018;10:123–134. doi:10.2147/CPAA.S14611530310332
   PubMed Web of Science ®Google Scholar
• BudhaNR, FrymoyerA, SmelickGS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther. 2012;92(2):203–213. doi:10.1038/clpt.2012.7322739140
   PubMed Web of Science ®Google Scholar
• WillemsenAE, LubbermanFJ, TolJ, et al. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016;21(6):962–976. doi:10.1016/j.drudis.2016.03.00226995271
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Clinical pharmacology and biopharmaceutics reviews. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202570Orig1s000harmR.pdf. Accessed 12 1, 2019.
   Google Scholar
• US Food and Drug Administration. Clinical pharmacology and biopharmaceutics reviews. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205755Orig1s000ClinPharmR.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• LauYY, GuW, LinT, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(6):1119–1128. doi:10.1007/s00280-017-3308-728424965
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Clinical pharmacology and biopharmaceutics reviews. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/208434Orig1s000ClinPharmR.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• ParrottNJ, YuLJ, TakanoR, et al. Physiologically based absorption modeling to explore the impact of food and gastric pH changes on the pharmacokinetics of alectinib. AAPS J. 2016;18(6):1464–1474. doi:10.1208/s12248-016-9957-327450228
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Chemistry Reviews. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000ChemR.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• US Food and Drug Administration. Chemistry reviews. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000ChemR.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• European Medicines Agency. Multi-discipline review. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210868Orig1s000MultidisciplineR.pdf. Accessed 49, 2020 Accessed 12 8, 2019.
   Google Scholar
• KoziolekM, AlcaroS, AugustijnsP, et al. The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group. Eur J Pharm Sci. 2019;134:31–59. doi:10.1016/j.ejps.2019.04.00330974173
   PubMed Web of Science ®Google Scholar
• DengJ, ZhuX, ChenZ, et al. A Review of food-drug interactions on oral drug absorption. Drugs. 2017;77(17):1833–1855. doi:10.1007/s40265-017-0832-z29076109
   PubMed Web of Science ®Google Scholar
• XuH, O’GormanM, BoutrosT, et al. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. J Clin Pharmacol. 2015;55(1):104–113. doi:10.1002/jcph.35624990113
   PubMed Web of Science ®Google Scholar
• OtoukeshS, SanchezT, MirshahidiS, et al. ASCEND-8 pharmacokinetic, safety, and efficacy data for ceritinib 450 mg with food in patients with anaplastic lymphoma kinase-positive non-small cell lung Cancer: a clinical perspective. Cancer Treat Res Commun. 2019;20:100149. doi:10.1016/j.ctarc.2019.10014931075537
   PubMedGoogle Scholar
• ChoBC, KimDW, BearzA, et al. ASCEND-8: a randomized phase 1 Study of Ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with anaplastic lymphoma kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol. 2017;12(9):1357–1367. doi:10.1016/j.jtho.2017.07.00528729021
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. Available from: https://www.ema.europa.eu/en/documents/assessment-report/alecensa-epar-public-assessment-report_en.pdf. Accessed 49, 2020 Accessed 12 1, 2019.
   Google Scholar
• TugnaitM, GuptaN, HanleyMJ, et al. The Effect of a high-fat meal on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(6):734–741. doi:10.1002/cpdd.64130570839
   PubMed Web of Science ®Google Scholar
• YuJ, PetrieID, LevyRH, et al. Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. food and drug administration in 2017. Drug Metab Dispos. 2019;47(2):135–144. doi:10.1124/dmd.118.08490530442649
   PubMed Web of Science ®Google Scholar
• NakanishiT, TamaiI. Interaction of drug or food with drug transporters in intestine and liver. Curr Drug Metab. 2015;16(9):753–764. doi:10.2174/13892002160915120111353726630906
   PubMed Web of Science ®Google Scholar
• KönigJ, MüllerF, FrommMF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944–966. doi:10.1124/pr.113.00751823686349
   PubMed Web of Science ®Google Scholar
• TangSC, NguyenLN, SparidansRW, et al. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134(6):1484–1494. doi:10.1002/ijc.2847524037730
   PubMed Web of Science ®Google Scholar
• ShuW, MaL, HuX, et al. Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2. Eur J Pharm Sci. 2020;142:105153. doi:10.1016/j.ejps.2019.10515331740393
   PubMed Web of Science ®Google Scholar
• OmoteS, MatsuokaN, ArakawaH, et al. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep. 2018;8(1):9237. doi:10.1038/s41598-018-27672-y29915248
   PubMed Web of Science ®Google Scholar
• SatoT, MishimaE, ManoN, et al. Potential drug interactions mediated by renal organic anion transporter OATP4C1. J Pharmacol Exp Ther. 2017;362(2):271–277. doi:10.1124/jpet.117.24170328550055
   PubMed Web of Science ®Google Scholar
• RazaA, KoppSR, KotzeAC. Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro. Vet Parasitol. 2016;227:64–68. doi:10.1016/j.vetpar.2016.07.02627523939
   PubMed Web of Science ®Google Scholar
• KurataY, IeiriI, KimuraM, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol. 2002;72:209–219.
   Google Scholar
• SakaedaT, NakamuraT, OkumuraK. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4(4):397–410. doi:10.1517/phgs.4.4.397.2274712831320
   PubMed Web of Science ®Google Scholar
• DessillyG, ElensL, PaninN, et al. ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics. 2016;17(8):883–890. doi:10.2217/pgs-2016-001227268766
   PubMed Web of Science ®Google Scholar
• FujiwaraY, HamadaA, MizugakiH, et al. Pharmacokinetic profiles of significant adverse events with crizotinib in Japanese patients with ABCB 1 polymorphism. Cancer Sci. 2016;107(8):1117–1123. doi:10.1111/cas.1298327270784
   PubMed Web of Science ®Google Scholar
• HuJ, ZhangX, WangF, et al. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2overexpressing cells in vitro and in vivo. Oncotarget. 2015;6(42):44643–44659. doi:10.18632/oncotarget.598926556876
   PubMedGoogle Scholar
• YangL, LiM, WangF, et al. Ceritinib enhances the efficacy of substrate chemotherapeutic agent in human ABCB1-overexpressing leukemia cells in vitro,in vivo and ex-vivo. Cell Physiol Biochem. 2018;46(6):2487–2499. doi:10.1159/00048965529742496
   PubMedGoogle Scholar
• HofmanJ, SorfA, VagiannisD, et al. Interactions of alectinib with human ATP-binding cassette drug efflux transporters and cytochrome P450 biotransformation enzymes: effect on pharmacokinetic multidrug resistance. Drug Metab Dispos. 2019;47(7):699–709. doi:10.1124/dmd.119.08697531068367
   PubMed Web of Science ®Google Scholar
• YangK, ChenY, ToKK, et al. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro,in vivo and ex vivo. Exp Mol Med. 2017;49(3):e303. doi:10.1038/emm.2016.16828303028
   PubMed Web of Science ®Google Scholar
• ThelenK1, DressmanJB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol. 2009;61(5):541–558. doi:10.1211/jpp.61.05.000219405992
   PubMed Web of Science ®Google Scholar
• XieF, DingX, ZhangQY. An update on the role of intestinal cytochrome P450 enzymes in drug disposition. Acta Pharm Sin B. 2016;6(5):374–383. doi:10.1016/j.apsb.2016.07.01227709006
   PubMed Web of Science ®Google Scholar
• RobertsJA1, PeaF, LipmanJ. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1–8. doi:10.1007/s40262-012-0018-523150213
   PubMed Web of Science ®Google Scholar
• BenetLZ, HoenerBA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71(3):115–121. doi:10.1067/mcp.2002.12182911907485
   PubMed Web of Science ®Google Scholar
• HaddadA, DavisM, LagmanR. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer. 2007;15(3):251. doi:10.1007/s00520-006-0127-517139496
   PubMed Web of Science ®Google Scholar
• KortA, SparidansRW, WagenaarE, et al. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res. 2015;102:200–207. doi:10.1016/j.phrs.2015.09.00326361725
   PubMed Web of Science ®Google Scholar
• ManikandanP, NaginiS. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19(1):38–54. doi:10.2174/138945011866617012514455728124606
   PubMed Web of Science ®Google Scholar
• XuH, O’GormanM, TanW, et al. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects. Eur J Clin Pharmacol. 2015;71(12):1441–1449. doi:10.1007/s00228-015-1945-526381275
   PubMed Web of Science ®Google Scholar
• LinS, NickensDJ, PatelM, et al. Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2019;84(1):203–211. doi:10.1007/s00280-019-03861-y31127319
   PubMed Web of Science ®Google Scholar
• MaoJ, JohnsonTR, ShenZ, et al. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013;41(2):343–352. doi:10.1124/dmd.112.04911423129213
   PubMed Web of Science ®Google Scholar
• KubomuraY, IseY, WakoT, et al. A drug interaction between crizotinib and warfarin in non-small-cell lung cancer: a case report. J Nippon Med Sch. 2017;84(6):291–293. doi:10.1272/jnms.84.29129279560
   PubMed Web of Science ®Google Scholar
• MorcosPN, ClearyY, GueriniE, et al. Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev. 2017;6(3):280–291. doi:10.1002/cpdd.29827545757
   PubMed Web of Science ®Google Scholar
• TugnaitM, GuptaN, HanleyMJ, et al. Effects of strong CYP2C8 or CYP3A Inhibition and CYP3A induction on the pharmacokinetics of brigatinib, an oral anaplastic lymphoma kinase inhibitor, in healthy volunteers. Clin Pharmacol Drug Dev. 2019;8(6):734–741. doi:10.1002/cpdd.72330570839
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report. Available from: https://www.ema.europa.eu/en/documents/assessment-report/alunbrig-epar-public-assessment-report_en.pdf. Accessed 49, 2020 Accessed 12 2, 2019.
   Google Scholar
• FengB, VarmaMV. Evaluation and quantitative prediction of renal transporter-mediated drug-drug interactions. J Clin Pharmacol. 2016;56(7):S110–S121. doi:10.1002/jcph.70227385169
   PubMed Web of Science ®Google Scholar
• PatelM, TaskarKS, Zamek-GliszczynskiMJ. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. J Clin Pharmacol. 2016;56(7):S23–S39. doi:10.1002/jcph.67127385177
   PubMed Web of Science ®Google Scholar
• KrensSD, LasscheG, JansmanFGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20(4):e200–e207. doi:10.1016/S1470-2045(19)30145-730942181
   PubMed Web of Science ®Google Scholar
• VerbeeckRK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;64(12):1147–1161. doi:10.1007/s00228-008-0553-z18762933
   PubMed Web of Science ®Google Scholar
• VerbeeckRK, MusuambaFT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–773. doi:10.1007/s00228-009-0678-819543887
   PubMed Web of Science ®Google Scholar
• El-KhoueiryAB, SarantopoulosJ, O’BryantCL, et al. Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. Cancer Chemother Pharmacol. 2018;81(4):659–670. doi:10.1007/s00280-018-3517-829468455
   PubMed Web of Science ®Google Scholar
• TanW, YamazakiS, JohnsonTR, et al. Effects of renal function on crizotinib pharmacokinetics: dose recommendations for patients with ALK-positive non-small cell lung cancer. Clin Drug Investig. 2017;37(4):363–373. doi:10.1007/s40261-016-0490-z
   PubMed Web of Science ®Google Scholar
• MorcosPN, ClearyY, Sturm-PellandaC, et al. Effect of hepatic impairment on the pharmacokinetics of alectinib. J Clin Pharmacol. 2018;58(12):1618–1628. doi:10.1002/jcph.128630052269
   PubMed Web of Science ®Google Scholar
• RoccoD, BattiloroC, Della GravaraL, et al. Safety and tolerability of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Drug Saf. 2019;42(2):199–209. doi:10.1007/s40264-018-0771-y30649741
   PubMed Web of Science ®Google Scholar
• Cholewka-StafińskaM, PolaniakR, KardasM, et al. Interaction of oral form anticancer drugs with grapefruit juice. Pol Merkur Lekarski. 2017;42(247):30–33.28134229
   PubMedGoogle Scholar
• LevêqueD, LemachattiJ, NivoixY, et al. Mechanisms of pharmacokinetic drug-drug interactions. Rev Med Interne. 2010;31(2):170–179. doi:10.1016/j.revmed.2009.07.00919740579
   PubMed Web of Science ®Google Scholar